Hep C drugs to get TGA approval

Two of the new direct-acting antiviral drugs that are revolutionising the treatment of chronic hepatitis C have been recommended for approval in Australia by the Secretary to the Department of Health.

Simeprevir, a NS3/4A protease inhibitor, was recommended for inclusion to Schedule 4 for the treatment of genotype 1 and 4 infections, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease including cirrhosis, with or without HIV co-infection.

The drug